Drug Name: Cibinqo
Indications: To treat refractory, moderate-to-severe atopic dermatitis. Cibinqo is a Janus Kinase (JAK) inhibitor that is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Active Ingredient: Abrocitinib
Company: Pfizer, Inc.
Approval Date: 1/14/2022
More Details: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cibinqo